Public Summary Sample Clauses

Public Summary. This document is the Innovation Plan for the Centre of Excellence (XxX) for Computational Biomedicine (CompBioMed), applicable to Phase 2 of the XxX (CompBioMed 2) and building on the innovation infrastructure established during the first 3 years of operation of the XxX in Phase 1 (CompBioMed 1). The plan outlines how all services, software and know-how developed during the project can be assessed for their innovation potential. It provides guidance to support individual researchers in making that assessment and undertaking any planning of specific exploitation routes. The innovation management activities during CompBioMed 1 have resulted in a substantial funded programme of development across our core work packages, taking our software and services to full usability by the biomedical community. These work packages will also determine the role our XxX will play in supporting that community in their use in the future. This plan is complementary to the core funded activities and will maintain the internal infrastructure to support the addition of new results to the innovation process.
Sample 1Sample 2
AutoNDA by SimpleDocs
Public Summary. The Project Handbook (PH) for CompBioMed2 is a document describing the project organisation and internal procedures. In a project of this size it is vital that all partners communicate effectively but without adding undue pressure to their business as usual. The CompBioMed2 project handbook details the procedure for documentation management, communication mechanisms and deliverable submission control. Its main goal is to allow easy access to communication methods and to the management structure by acting as a reference document for all the partners to ensure that project outcomes are uniform and accessible.
Sample 1
Public Summary. Work Package 2 (WP2) in the CompBioMed 2 project aggregates the computational biomedical research activities of the project. The leader of this work package is the University of Amsterdam (UvA). Computational Biomedicine is highly diverse, subsuming a large range of modelling and simulation methods, each applicable to a specific level of human bodily organisation. State of the art mathematical models in Computational Biomedicine need to take into account the inherent multiphysics and multiscale character of human physiology. This means that, typically, different types of models, representing different scales within a given (patient specific) biomedical system, often need to be taken into account, including the details as to how to correctly connect these different models. The main objective of this work package is to lay the groundwork for the application of High Performance Computer (HPC)-based Computational Biomedicine approaches to a great number of therapeutic areas. The HPC requirements of our users are as diverse as the communities we represent; therefore, we must support both monolithic codes, potentially scaling to the exascale, and complex workflows requiring support for advanced execution patterns on a range of diverse and geographically distributed platforms.
Sample 1
Public Summary. Work Package 2 (WP2) in the CompBioMed2 project aggregates the computational biomedical research activities of the project. The leader of this work package is the University of Amsterdam (UvA). Computational Biomedicine is highly diverse, subsuming a large range of modelling and simulation methods, each applicable to a specific level of human body organisation. State of the art mathematical models in Computational Biomedicine need to take into account the inherent multiphysics and multiscale character of human physiology. This means that, typically, different types of models, representing different scales within a given (patient specific) biomedical system, often need to be taken into account, including the details as to how to correctly connect these different models. The main objective of this work package is to lay the groundwork for the application of High Performance Computer (HPC)-based Computational Biomedicine approaches to a great number of therapeutic areas. The HPC requirements of our users are as diverse as the communities we represent; therefore, we must support a wide palette of codes potentially scaling to the exascale. These codes can be categorised based on their execution pattern as (I) monolithic code, (II) coupled code, or (III) complex workflow requiring support for advanced execution patterns on a range of diverse and geographically distributed platforms. This document reports on the scientific progress achieved within our application portfolio and includes a list and description of the publicly available user resources that aim to enable efficient external code adoption and that will collectively form the “best practices” guide for external users.
Sample 1
Public Summary. The document reports the process for establishment of the CompBioMed2 Ethics Panel, production of an Ethics Questionnaire, and circulation of the questionnaire to project partners, and summarises the outcomes from this process. The outcomes of the questionnaire were used to produce this Ethics Report at M06 of project activity, which is provided in Section 9 of this document. Section 8.5 describes the process that will be used to ensure ongoing monitoring of the ethical status of CompBioMed2 research activity throughout the project and how this will be used to keep the Ethics Report up to date.
Sample 1
Public Summary. CompBioMed is a user-driven Centre of Excellence which serves users from academia, industry, and clinical practice in promoting and enhancing computational methods and simulation tools in the biomedical domain. The Centre of Excellence (XxX) is also working as contact point for our users’ community by acting as network and incubator centre to promote application usage and integration, through specialised training and support activities. The impact of the XxX within the Computational Biomedicine user community is critically dependent on the ability of the XxX to translate the work done within the consortium partners into tangible and usable services which can help to bring value to the end users. Since the inception of CompBioMed2, leveraging the simulation community that has grown out of CompBioMed1, we have built several core services which are maintained and offered to our userbase. These services have been designed to support the needs of the biomedical community in delivering state of the art solutions, access to training material and efficient use of high- performance and high-throughput infrastructures. This deliverable describes the compute and data services developed and delivered within the project. The first part of the document focuses on the applications services available through the project partners, providing an overview of technical characteristics and infrastructure usage. In the second part of the document, we describe the tools and support activities we have been working on in these first 24 months of the project. The goal is to help our partners to deliver mature biomedical solutions and performance improvement, future proofing of biomedical applications, preparing strategies and best practice to exploit current multi-petaflop and emerging exascale resources.
Sample 1
Public Summary. The Commissioner shall make available to the public a summary of the report required by sub- section (a) that includes, at a minimum—
Sample 1
AutoNDA by SimpleDocs
Public Summary. CompBioMed is a user-driven Centre of Excellence which serves users from academia, industry and clinical practice in promoting and enhancing computational methods and simulation tools in the biomedical domain. The Centre of Excellence (XxX) is also working as contact point for our users’ community by acting as network and incubator centre to promote application usage and integration, through specialised trainings and support activities. The impact of the XxX within the Computational Biomedicine user community is critically dependent on the ability of the XxX to translate the work done within the consortium partners into tangible and usable services which can help to bring value to the end users. Since the inception of CompBioMed2, leveraging the simulation community grown out of CompBioMed1, we have built several core services which are maintained and offered to our userbase. These services have been designed to support the needs of the biomedical community in delivering state of the art solutions, access to training material and efficient use of high- performance and high-throughput infrastructures. This deliverable presents an overview of the existing CompBioMed services and we propose a set of guidelines and standards that will help in publishing the service portfolio and to enrich the service offering with more community-driven biomedical solutions. In this work we focus our attention on the currently available services within the project in order to define a service management system, and our plans for its development, to support the delivery of mature compute and data services for the community, which is the real focus of our work in CompBioMed.
Sample 1

Related to Public Summary

  • SUMMARY As provided in the Fifth Amended and Restated Declaration of Trust and Trust Agreement of the Trust, as amended from time to time (the “Trust Agreement”) as currently in effect and described in the applicable Prospectus (defined below), units of fractional undivided beneficial interest in and ownership of each Fund (individually and collectively, the “Shares”) may be created or redeemed by the Managing Owner for an Authorized Participant in aggregations of two hundred thousand (200,000) Shares (each aggregation, a “Basket”). Baskets are offered only pursuant to the applicable registration statement of the Trust, with respect to all the Funds, excluding the DBA Fund and the DBS Fund, on Form S-3, with respect to the DBA Fund on Form S-3ASR, and with respect to the DBS Fund on Form S-1, as amended (Registration Nos.: 333-203008 et seq. with respect to all the Funds, excluding the DBA Fund and the DBS Fund; Registration Nos.: 333-185865 et seq. with respect to the DBA Fund only; Registration Nos.: 333-193222 et seq. with respect to the DBS Fund only), as currently effective and on file with the Securities and Exchange Commission (“SEC”) and as the same may be amended from time to time thereafter or any successor registration statement in respect of Shares of each Fund (each, a “Registration Statement,” collectively, the “Registration Statements”) together with the prospectuses of the Trust in the form filed with the SEC under Rule 424(b) under the Securities Act of 1933, as amended (the “1933 Act”), after the effectiveness of the Registration Statements (each, a “Prospectus,” collectively, the “Prospectuses”). Under the Trust Agreement, the Managing Owner is authorized to issue Baskets to, and redeem Baskets from, Authorized Participants, (i) through the Continuous Net Settlement (“CNS”) clearing processes of the National Securities Clearing Corporation (the “NSCC”) as such processes have been enhanced to effect purchases and redemptions of Creation Baskets and Redemption Baskets (the “CNS Clearing Process”), or (ii) if outside the CNS Clearing Process, only through the facilities of The Depository Trust Company (“DTC” or the “Depository”) (the “DTC Process”), or a successor depository, and only in exchange for cash. This Agreement sets forth the specific procedures by which an Authorized Participant may create or redeem Baskets. For the avoidance of doubt, the term “Prospectus” shall mean the Prospectus for the DBA Fund, the Prospectus for the DBS Fund or the Prospectus for all of the Funds, excluding the DBA Fund and the DBS Fund, as the context requires. Because new Shares for each Fund can be created and issued by the Trust on an ongoing basis, at any point during the life of each respective Fund, a “distribution,” as such term is used in the 1933 Act, may be occurring. The Authorized Participant is cautioned that some of its activities may result in its being deemed a participant in a distribution in a manner that would render it a statutory underwriter and subject it to the prospectus delivery and liability provisions of the 1933 Act. The Authorized Participant should review the “Plan of Distribution” section of the applicable Prospectus and consult with its own counsel in connection with entering into this Agreement and submitting a Purchase Order Subscription Agreement (defined below). Capitalized terms used but not defined in this Agreement shall have the meanings assigned to such terms in the Trust Agreement. To the extent there is a conflict between any provision of this Agreement and the provisions of the Trust Agreement, the provisions of the Trust Agreement shall control. To the extent there is a conflict between any provision of this Agreement and the provisions of the applicable Prospectus, the applicable Prospectus shall control. For the avoidance of doubt, any action which is an action being taken by the Managing Owner may be taken by a party whom the Managing Owner has duly authorized to take such action. To give effect to the foregoing premises and in consideration of the mutual covenants and agreements set forth below, the parties hereto agree as follows:

  • JOB SUMMARY Vouches sample transaction in audit verification assignments and submits findings to supervisor; • Records proceedings of entry and exit conferences; • Collects and analyses data and statistics; • Prepares audit working papers for review by supervisor; • Supervises subordinate staff; • Undertakes any other duties that may be assigned by the Internal Auditor.

  • Budget Summary Other Sources (Page BudgetSum 2-3 - Acct 7000), must equal Other Uses (BudgetSum 2-3 - Acct. 8000). Estimated Beginning Fund Balance July,1 2020 for all Funds (Cells C3 - K3) (Line must have a number or zero. Do not leave blank.) OK Estimated Activity Fund Beginning Fund Balance July,1 2020 (Cell C83) (Cell must have a number or zero. Do not leave blank.) OK Transfer Among Funds (Funds 10, 20, 40 - Acct 7130 - Cells C29, D29, F29), must equal (Funds 10, 20 & 40 - Acct 8130 - Cells C52, D52, F52). OK Transfer of Interest (Funds 10 thru 90 - Acct 7140 - Cells C30:K30), must equal (Funds 10 thru 60, & 80 - Acct 8140 - Cells C53:H53, J53). OK Transfer to Debt Service to Pay Principal on Capital Leases (Fund 30 - Acct 7400 - Cell E39) must equal (Funds 10, 20 & 60 - Acct 8400 Cells C57:H60). OK Transfer to Debt Service to Pay Interest on Capital Leases (Fund 30 - Acct 7500 - Cell E40) must equal (Funds 10, 20 & 60 - Acct 8500 - Cells C61:H64). OK Transfer to Debt Service Fund to Pay Principal on Revenue Bonds (Fund 30 - Acct 7600 - Cell E41) must equal (Funds 10 & 20 - Acct 8600 - Cells C65:D68). OK Transfer to Debt Service to Pay Interest on Revenue Bonds (Fund 30 - Acct 7700 - Cell E42) must equal (Funds 10 & 20 - Acct 8700 - Cells C69:D72). OK Transfer to Capital Projects Fund (Fund 60 - Acct 7800 - Cell H43) must equal (Fund 10 & 20, Acct 8800 - Cells C73:D76). OK

  • Executive Summary Based on the requirements and qualifications set forth in the Pooling and Servicing Agreement, as well as the items listed below, the Trust Advisor has undertaken a limited review of the Special Servicer’s operational activities to service the Specially Serviced Mortgage Loans in accordance with the Servicing Standard. Based on such review, the Trust Advisor [does, does not] believe there are material violations of the Special Servicer’s compliance with its obligations under the Pooling and Servicing Agreement. In addition, the Trust Advisor notes the following: [PROVIDE SUMMARY OF INFORMATION]. In connection with the assessment set forth in this report:

  • WHO WILL REVIEW THE INFORMATION DISCLOSED ON THE RELATIONSHIP DISCLOSURE FORM AND ANY UPDATES? The information disclosed on this form and any updates will be a public record as defined by Chapter 119, Florida Statutes, and may therefore be inspected by any interested person. Also, the information will be made available to the Mayor and the BCC members. This form and any updates will accompany the information for the applicant’s project or item. However, for development-related items, if an applicant discloses the existence of one or more of the relationships described above and the matter would normally receive final consideration by the Concurrency Review Committee or the Development Review Committee, the matter will be directed to the BCC for final consideration and action following committee review.

  • Root-­‐zone Information Publication ICANN’s publication of root-­‐zone contact information for the TLD will include Registry Operator and its administrative and technical contacts. Any request to modify the contact information for the Registry Operator must be made in the format specified from time to time by ICANN at xxxx://xxx.xxxx.xxx/domains/root/.

  • Non-Public Information Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Purchaser shall have entered into a written agreement with the Company regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

  • Exchange Control Information Exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers. If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.

Time is Money Join Law Insider Premium to draft better contracts faster.